331 results on '"Bansal, Radhika"'
Search Results
2. Contribution of ICT in Agriculture: A Comparative Analysis of Warana & Ikisan
3. A Framework for Ranking Content Providers Using Prompt Engineering and Self-Attention Network
4. Single Nucleotide Polymorphism of Leptin Receptor Gene in Type 2 Diabetes Mellitus: A Cross-sectional Study
5. Local Life: Stay Informed Around You, A Scalable Geoparsing and Geotagging Approach to Serve Local News Worldwide
6. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions
7. Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management
8. Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma
9. Variety-based physical characterization and pre-gelatinization-induced functional-rheological changes in kidney beans
10. What's happening in your neighborhood? A Weakly Supervised Approach to Detect Local News
11. Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience.
12. Outcomes of patients with R/R B-cell NHL and limited (
13. Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity
14. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
15. Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma
16. Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma
17. Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality
18. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma
19. Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma
20. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
21. Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report
22. CMOS-compatible Self-powered Short-wave Infrared Imagers Based on GeSn Photodetector Arrays
23. Metformin and cytokine release syndrome after immune effector cell therapy.
24. Factors before leukapheresis that correlate with severe cytopenia and therapy related myeloid neoplasm post CAR-T.
25. Class comparison of BCMA-directed therapies in relapsed multiple myeloma.
26. Real world outcome of patients with multiple myeloma who received bispecific antibodies after CAR-T therapy.
27. Incidence and Risk Factors for Acute Kidney Injury After Chimeric Antigen Receptor T-Cell Therapy
28. Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT
29. Uncertainty-informed deep learning models enable high-confidence predictions for digital histopathology
30. Serial Evaluation of Preimmunization Antibody Titers in Lymphoma Patients Receiving Chimeric Antigen Receptor T Cell Therapy
31. High-performance Ge-on-insulator lateral p-i-n waveguide photodetectors for electronic–photonic integrated circuits at telecommunication wavelengths
32. Outpatient Management of CAR-T and Teclistamab for Patients with Lymphoma and Multiple Myeloma
33. Co-overexpression of genes in plants for abiotic stress tolerance
34. Contributors
35. Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma
36. Temperature-Dependent Characteristics of GeSn Waveguide p-i-n Photodetectors: Step Towards Cryogenic Silicon Photonics
37. Temperature-Dependent Characteristics of GeSn Waveguide p-i-n Photodetectors: Step Towards Cryogenic Silicon Photonics
38. Extramedullary disease in multiple myeloma
39. Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clinic experience.
40. POSTER: ABCL-673 Single Cell Analysis Reveals Immune Dysfunction in Large B-Cell Lymphoma (LBCL) Patients With Hypomagnesemia Receiving Axi-Cel: Results from ZUMA-1 Trial and Mayo Clinic Cohort
41. P-003 Clinical outcomes among multiple myeloma and lymphoma patients taking beta-blockers undergoing CAR-T therapy
42. MM-527 Real World Evaluation of Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM)
43. P-049 Safety and efficacy of standard of care ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM): real world experience
44. POSTER: MM-527 Real World Evaluation of Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM)
45. ABCL-673 Single Cell Analysis Reveals Immune Dysfunction in Large B-Cell Lymphoma (LBCL) Patients With Hypomagnesemia Receiving Axi-Cel: Results from ZUMA-1 Trial and Mayo Clinic Cohort
46. S263: CYTOPENIAS, AGE AND CAR-HEMATOTOX SCORE PREDICT THE DEVELOPMENT OF POST CAR T-CELL THERAPY-RELATED MYELOID NEOPLASMS
47. Impact of Rituximab and Corticosteroids on Late Cytopenias Post-Chimeric Antigen Receptor T Cell Therapy
48. CT-016 Prognostic Role of Lymphocyte-to-Monocyte Ratio in Patients Treated With CAR-T for Aggressive Lymphoma
49. Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma
50. Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.